Author

Carmela Baviello

Institutions: University of Molise, National Research Council

Observed institutions: University of Molise, National Research Council

ORCID: 0009-0005-3797-0507

Observed ORCID: 0009-0005-3797-0507

OpenAlex ID: A5119154116

KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion

2026 · Daniela Criscuolo, Rosaria Catalano, et al. · APOPTOSIS

Figure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Supplementary Methods from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure 1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Data from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure 2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

2026 · Daniela Criscuolo, Francesco Merolla, et al.

Works count: 12

Citation count:

H-index:

I10-index: